Investigating the Role of Resistance Exercise Frequency in the Regulation of Skeletal Muscle Mass (EXFREQ)

January 3, 2023 updated by: University of Birmingham
This study will investigate whether manipulating resistance exercise frequency impacts muscle protein synthesis rates. The investigators will test the hypothesise that a higher resistance exercise frequency will result in greater muscle protein synthesis rates than a lower resistance exercise frequency.

Study Overview

Detailed Description

Resistance exercise is currently the most effective means of building or maintaining muscle mass. Resistance exercise guidelines generally suggest that those looking to increase muscle mass should train each muscle group once to twice per week. However, it has been proposed that it may be of greater benefit to train a muscle group with a higher frequency (i.e., four to six times per week) than currently suggested. If true, completing the same total volume of resistance exercise in more frequent, smaller bouts could prove to be a more beneficial strategy to optimally build or maintain muscle mass.

Therefore, this study will investigate whether manipulating resistance exercise frequency impacts cumulative muscle protein synthesis rates in young individuals. Participants will undergo a 7 day period of habitual activity before completing the same total volume of resistance exercise as either; i) one isolated bout (low frequency) or ii) five smaller bouts (high frequency) over a period of 7 days.

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • West Midlands
      • Birmingham, West Midlands, United Kingdom, B15 2TT
        • School of Sport Exercise and Rehabilitation Sciences, University of Birmingham

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Body mass index (18.5-29.99 kg/m2)
  • Untrained - defined as: Perform activities of daily living and recreation but have completed no regular lower body resistance-type exercise (e.g., weight training) activity in the last year.
  • Good general health

Exclusion Criteria:

  • Lidocaine allergy
  • Hypertension (≥140/90 mmHg)
  • Current participation in another clinical study
  • Previous participation in this study
  • Bleeding disorder/s
  • Current or recent smoker
  • Vegetarian or vegan
  • Past history of substance abuse and/or taking prescription or non-prescription medication (e.g., beta-blockers, insulin or thyroxine) or supplements that may influence normal metabolic responses.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low Frequency Condition
Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
Experimental: High Frequency Condition
Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in muscle protein synthesis (FSR %/day)
Time Frame: At day 10 and 15.
The change in muscle protein synthesis rates (FSR %/day) from baseline will be determined between the low and high frequency conditions at days 10 and 15 using deuterium oxide (D2O).
At day 10 and 15.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in satellite cell response
Time Frame: At day 10 and 15.
The change in acute satellite cell response will be determined in muscle samples following low and high frequency resistance exercise at days 10 and 15.
At day 10 and 15.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Gareth Wallis, PhD, University of Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2018

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

August 31, 2017

First Submitted That Met QC Criteria

September 5, 2017

First Posted (Actual)

September 8, 2017

Study Record Updates

Last Update Posted (Actual)

January 5, 2023

Last Update Submitted That Met QC Criteria

January 3, 2023

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • ERN_17-0997

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Physical Activity

Clinical Trials on Low Frequency Condition

3
Subscribe